Cibc World Market Inc. Has $8.25 Million Stake in Becton, Dickinson and Company $BDX

Cibc World Market Inc. increased its position in Becton, Dickinson and Company (NYSE:BDX) by 89.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 44,098 shares of the medical instruments supplier’s stock after purchasing an additional 20,857 shares during the quarter. Cibc World Market Inc.’s holdings in Becton, Dickinson and Company were worth $8,254,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Brighton Jones LLC raised its position in Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after purchasing an additional 877 shares in the last quarter. Empowered Funds LLC grew its stake in shares of Becton, Dickinson and Company by 20.4% in the 1st quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier’s stock valued at $1,827,000 after purchasing an additional 1,354 shares during the period. CWM LLC raised its holdings in shares of Becton, Dickinson and Company by 87.7% in the 2nd quarter. CWM LLC now owns 22,596 shares of the medical instruments supplier’s stock worth $3,892,000 after buying an additional 10,560 shares in the last quarter. Sequoia Financial Advisors LLC lifted its position in shares of Becton, Dickinson and Company by 43.6% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 8,441 shares of the medical instruments supplier’s stock worth $1,454,000 after buying an additional 2,562 shares during the period. Finally, NorthRock Partners LLC bought a new position in shares of Becton, Dickinson and Company during the 2nd quarter worth approximately $325,000. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Down 1.0%

Shares of NYSE:BDX opened at $175.95 on Friday. The company has a quick ratio of 0.64, a current ratio of 1.05 and a debt-to-equity ratio of 0.67. The firm has a market cap of $50.10 billion, a P/E ratio of 28.70, a P/E/G ratio of 2.32 and a beta of 0.25. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $185.02. The company’s 50-day moving average price is $198.82 and its two-hundred day moving average price is $192.20.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.81 by $0.10. The company had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.15 billion. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. Becton, Dickinson and Company’s quarterly revenue was up 1.6% on a year-over-year basis. During the same period in the prior year, the business earned $3.43 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. As a group, research analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Stockholders of record on Tuesday, March 10th will be given a dividend of $1.05 per share. The ex-dividend date is Tuesday, March 10th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.4%. Becton, Dickinson and Company’s payout ratio is presently 68.52%.

Becton, Dickinson and Company announced that its board has authorized a share buyback program on Tuesday, January 27th that allows the company to buyback $10.00 million in shares. This buyback authorization allows the medical instruments supplier to purchase up to 0% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s board of directors believes its stock is undervalued.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on BDX shares. Barclays assumed coverage on Becton, Dickinson and Company in a research note on Tuesday. They set an “overweight” rating and a $202.00 price objective for the company. Morgan Stanley increased their target price on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 2nd. TD Cowen lifted their price target on shares of Becton, Dickinson and Company from $183.00 to $189.00 and gave the company a “hold” rating in a report on Wednesday. Wells Fargo & Company decreased their price objective on shares of Becton, Dickinson and Company from $184.00 to $157.00 and set an “equal weight” rating on the stock in a research note on Tuesday. Finally, Jefferies Financial Group cut their target price on shares of Becton, Dickinson and Company from $220.00 to $190.00 and set a “buy” rating for the company in a research note on Tuesday. Five investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $195.46.

Key Stories Impacting Becton, Dickinson and Company

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: Citi raised its price target after a life‑sciences sale update, signaling potential value support if BDx proceeds with portfolio moves. Citi raises Becton Dickinson PT to $198
• Positive Sentiment: Jefferies issued a buy, supporting the view that BDx’s portfolio reshaping and product investments can sustain growth. Becton Dickinson Gets a Buy from Jefferies
• Positive Sentiment: TD Cowen nudged its target higher to $189 (hold), reflecting modest upside from current levels and adding another analyst vote of confidence. TD Cowen adjusts Becton Dickinson PT to $189
• Neutral Sentiment: Company Q4 review: management says portfolio reshaping and product investments offset tariff headwinds — useful context for earnings quality but not an immediate directional catalyst. BDX Q4 Deep Dive: Portfolio Reshaping and Product Investments Offset Tariff Headwinds
• Negative Sentiment: Zacks Research cut BDX from “hold” to “strong sell,” a notable downgrade that likely pressured sentiment and contributed to the share weakness. Zacks Research downgrade
• Negative Sentiment: AmericanBankingNews reports Citigroup lowered a prior target (headline shows a cut to $232), adding further mixed signals from the sell‑side. Citigroup Lowers Becton Dickinson PT to $232
• Negative Sentiment: JPMorgan and Wells Fargo issued pessimistic forecasts in separate notes, increasing analyst pressure and downside risk in the near term. JPMorgan pessimistic forecast Wells Fargo pessimistic forecast
• Negative Sentiment: Coverage flow drove a gap‑down headline after the analyst activity, reflecting short‑term selling pressure from downgrades and mixed guidance expectations. Shares gap down on analyst downgrade

Insider Activity

In related news, EVP Michael David Garrison sold 1,610 shares of the firm’s stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $207.46, for a total value of $334,010.60. Following the transaction, the executive vice president owned 12,095 shares in the company, valued at $2,509,228.70. This trade represents a 11.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 2,463 shares of company stock worth $501,530 over the last quarter. Corporate insiders own 0.40% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.